UNLABELLED: Fracture risk prediction can be enhanced by the concurrent assessment of other clinical risk factors. This study demonstrates that the estimation of an individual's 10-year probability of fracture by the FRAX algorithm identifies patients at high risk of fracture who will respond to bisphosphonate therapy. INTRODUCTION: Treatments for osteoporosis are targeted largely to patients with low bone density (BMD) or a prior fragility fracture. Fracture risk prediction can be enhanced by the concurrent assessment of other clinical risk factors, but it is important to determine whether the risk so identified can be reduced by intervention. We determined the effect of a bisphosphonate on fracture rates when risk was calculated using a new risk algorithm (FRAX). METHODS:Women aged 75 years or more were recruited to a randomised, double-blind controlled trial of 800 mg oral clodronate (Bonefos) daily over 3 years. Baseline clinical risk factors were entered in the FRAX model to compute the 10-year probability of major osteoporotic fractures with or without input of femoral neck BMD. The interaction between fracture probability and treatment efficacy was examined by Poisson regression. RESULTS: In 3,974 women, the interaction between fracture probability and treatment efficacy was significant when probability was assessed without BMD (p = 0.043), but not when BMD was included (p = 0.10). Efficacy was more evident in those deemed at highest risk. For example women lying at the 75th percentile of fracture probability in the absence of BMD (10-year probability 24%) treatment reduced fracture risk by 27% (HR 0.73, 95%CI 0.58-0.92). In those with a fracture probability of 30% (90th percentile), the fracture risk reduction was 38% (HR 0.62, 0.46-0.84). CONCLUSIONS: The estimation of an individual's 10-year probability of fracture by the FRAX algorithm identifies patients at high risk of fracture who will respond to bisphosphonate therapy.
RCT Entities:
UNLABELLED: Fracture risk prediction can be enhanced by the concurrent assessment of other clinical risk factors. This study demonstrates that the estimation of an individual's 10-year probability of fracture by the FRAX algorithm identifies patients at high risk of fracture who will respond to bisphosphonate therapy. INTRODUCTION: Treatments for osteoporosis are targeted largely to patients with low bone density (BMD) or a prior fragility fracture. Fracture risk prediction can be enhanced by the concurrent assessment of other clinical risk factors, but it is important to determine whether the risk so identified can be reduced by intervention. We determined the effect of a bisphosphonate on fracture rates when risk was calculated using a new risk algorithm (FRAX). METHODS:Women aged 75 years or more were recruited to a randomised, double-blind controlled trial of 800 mg oral clodronate (Bonefos) daily over 3 years. Baseline clinical risk factors were entered in the FRAX model to compute the 10-year probability of major osteoporotic fractures with or without input of femoral neck BMD. The interaction between fracture probability and treatment efficacy was examined by Poisson regression. RESULTS: In 3,974 women, the interaction between fracture probability and treatment efficacy was significant when probability was assessed without BMD (p = 0.043), but not when BMD was included (p = 0.10). Efficacy was more evident in those deemed at highest risk. For example women lying at the 75th percentile of fracture probability in the absence of BMD (10-year probability 24%) treatment reduced fracture risk by 27% (HR 0.73, 95%CI 0.58-0.92). In those with a fracture probability of 30% (90th percentile), the fracture risk reduction was 38% (HR 0.62, 0.46-0.84). CONCLUSIONS: The estimation of an individual's 10-year probability of fracture by the FRAX algorithm identifies patients at high risk of fracture who will respond to bisphosphonate therapy.
Authors: Stacey A Wainwright; Lynn M Marshall; Kristine E Ensrud; Jane A Cauley; Dennis M Black; Teresa A Hillier; Marc C Hochberg; Molly T Vogt; Eric S Orwoll Journal: J Clin Endocrinol Metab Date: 2005-02-22 Impact factor: 5.958
Authors: D M Black; M Steinbuch; L Palermo; P Dargent-Molina; R Lindsay; M S Hoseyni; O Johnell Journal: Osteoporos Int Date: 2001 Impact factor: 4.507
Authors: S T Harris; N B Watts; H K Genant; C D McKeever; T Hangartner; M Keller; C H Chesnut; J Brown; E F Eriksen; M S Hoseyni; D W Axelrod; P D Miller Journal: JAMA Date: 1999-10-13 Impact factor: 56.272
Authors: John A Kanis; Helena Johansson; Olof Johnell; Anders Oden; Chris De Laet; John A Eisman; Huibert Pols; Alan Tenenhouse Journal: Osteoporos Int Date: 2004-09-29 Impact factor: 4.507
Authors: John A Kanis; Olof Johnell; Dennis M Black; Robert W Downs; Somnath Sarkar; Thomas Fuerst; Roberta J Secrest; Imre Pavo Journal: Bone Date: 2003-09 Impact factor: 4.398
Authors: Eugene McCloskey; Peter Selby; Mike Davies; John Robinson; Roger M Francis; Judith Adams; Karthik Kayan; Monique Beneton; Tarja Jalava; Liisa Pylkkänen; Juha Kenraali; Sakari Aropuu; John A Kanis Journal: J Bone Miner Res Date: 2004-01-19 Impact factor: 6.741
Authors: Paul D Miller; Suna Barlas; Susan K Brenneman; Thomas A Abbott; Ya-Ting Chen; Elizabeth Barrett-Connor; Ethel S Siris Journal: Arch Intern Med Date: 2004-05-24
Authors: J A Kanis; H Johansson; A Oden; O Johnell; C De Laet; J A Eisman; E V McCloskey; D Mellstrom; L J Melton; H A P Pols; J Reeve; A J Silman; A Tenenhouse Journal: Bone Date: 2004-11 Impact factor: 4.398
Authors: Juliet E Compston; Nelson B Watts; Roland Chapurlat; Cyrus Cooper; Steven Boonen; Susan Greenspan; Johannes Pfeilschifter; Stuart Silverman; Adolfo Díez-Pérez; Robert Lindsay; Kenneth G Saag; J Coen Netelenbos; Stephen Gehlbach; Frederick H Hooven; Julie Flahive; Jonathan D Adachi; Maurizio Rossini; Andrea Z Lacroix; Christian Roux; Philip N Sambrook; Ethel S Siris Journal: Am J Med Date: 2011-11 Impact factor: 4.965
Authors: K Kayan; H Johansson; A Oden; S Vasireddy; K Pande; J Orgee; J A Kanis; E V McCloskey Journal: Osteoporos Int Date: 2009-05-13 Impact factor: 4.507
Authors: Andrew R Zullo; Tingting Zhang; Yoojin Lee; Kevin W McConeghy; Lori A Daiello; Douglas P Kiel; Vincent Mor; Sarah D Berry Journal: J Am Geriatr Soc Date: 2018-12-21 Impact factor: 5.562
Authors: Kristine E Ensrud; Li-Yung Lui; Brent C Taylor; John T Schousboe; Meghan G Donaldson; Howard A Fink; Jane A Cauley; Teresa A Hillier; Warren S Browner; Steven R Cummings Journal: Arch Intern Med Date: 2009-12-14